drugset / Trial / NCT00756509
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Timeline
- Start
- 2008-08-29
- Primary completion
- 2024-12-18
- Completion
- 2024-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nilotinib | Small molecule | 800 mg | Oral |